Saturday 17 October 2026
Export CCEL’s income statement to Excel — free account
Cryo-Cell International Inc.
CCEL Healthcare Medical Care Facilities
Cryo-Cell International Inc.’s revenue for fiscal 2025 (year ended November 2025) was $31.6 million, down 1.31% from fiscal 2024. In the quarter to August 2026, revenue was flat, EPS grew 77.8%, free cash flow fell 58.4% and total debt fell 29.5%, each against the same quarter a year earlier.
4.42
0.77
+21.10%
Follow CCEL
| Older periods | Nov '25 | Feb '26 | May '26 | Aug '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.02 | 0.84 | 0.92 | 1.09 | |
P/FCF ratio |
8.24 | 7.36 | 6.16 | 10.63 | |
P/Operating CF |
25.07 | 40.54 | 15.49 | 29.66 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.24 | 1.06 | 1.13 | 1.26 | |
EV/EBITDA |
20.99 | 21.01 | 27.30 | 25.19 | |
EV/Operating CF |
7.17 | 6.42 | 5.56 | 7.98 | |
EV/FCF |
10.08 | 9.26 | 7.56 | 12.33 | |
Quick Ratio |
0.51 | 0.55 | 0.63 | 0.72 | |
Current Ratio |
0.59 | 0.62 | 0.71 | 0.86 | |
Net Debt/EBITDA |
(1.98) | 6.14 | 3.18 | 1.51 | |
Debt/Assets |
16.96% | 15.98% | 13.31% | 12.91% | |
Debt/Equity |
(0.56) | (0.53) | (0.46) | (0.49) | |
Asset Turnover |
0.50 | 0.50 | 0.50 | 0.50 | |
Operating CF/Net income |
(0.34) | 13.84 | 3.33 | 0.90 | |
Capex/Depreciation |
(0.20) | (0.19) | (0.09) | (0.30) | |
Interest Coverage |
(8.23) | 1.65 | 2.71 | 5.01 | |
Research and Development Expense of Revenue |
1.08% | 0.86% | 1.28% | 0.69% | |
Selling, General and Administrative Expense of Revenue |
69.47% | 65.23% | 59.39% | 48.30% | |
Intangible Assets out of Total Assets |
0.05 | 0.05 | 0.05 | 0.04 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(2.14) | (2.58) | (2.35) | (1.93) | |
Graham Number |
4.01 | 4.14 | 3.88 | 3.27 | |
Earnings Yield |
(7.79%) | (10.19%) | (8.57%) | (5.58%) | |
Free Cash Flow Yield |
12.13% | 13.58% | 16.23% | 9.40% | |
Revenue per Share |
0.97 | 0.95 | 0.97 | 0.97 | |
Operating CF per Share |
0.16 | 0.08 | 0.23 | 0.14 | |
Capex per Share |
(0.01) | (0.01) | 0.00 | (0.01) | |
Free Cash Flow per Share |
0.15 | 0.07 | 0.23 | 0.13 | |
Cash per Share |
0.41 | 0.36 | 0.39 | 0.52 | |
Shareholders Equity per Share |
(2.31) | (2.28) | (2.20) | (2.03) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(2.31) | (2.28) | (2.20) | (2.03) | |
Free Cash Flow |
1.21 | 0.58 | 1.81 | 1.04 | |
Working Capital |
(8.03) | (6.69) | (4.63) | (2.16) | |
Capital Expenditures |
(0.07) | (0.07) | (0.03) | (0.10) | |
Net Current Asset Value |
(68.58) | (68.21) | (67.16) | (65.52) | |
EV/EBIT |
81.46 | 173.71 | 0.00 | 207.47 | |
Capex to Sales |
0.01 | 0.01 | 0.00 | 0.01 | |
Price to Operating Income |
66.58 | 138.04 | 0.00 | 178.89 | |
| Other line items | |||||
Average Receivables |
7.08 | 7.01 | 6.92 | 6.83 | |
Average Payables |
2.38 | 3.02 | 2.54 | 2.52 | |
Average Inventory |
0.53 | 0.54 | 0.49 | 0.59 | |
Average Assets |
63.20 | 62.63 | 62.57 | 62.74 | |
Average Common Equity |
(15.91) | (16.53) | (16.66) | (15.61) |
Columns are period end dates · fundamentals updated 15 Oct 2026